[go: up one dir, main page]

FR07C0073I2 - Vaccin contre le papillomavirus - Google Patents

Vaccin contre le papillomavirus

Info

Publication number
FR07C0073I2
FR07C0073I2 FR07C0073C FR07C0073C FR07C0073I2 FR 07C0073 I2 FR07C0073 I2 FR 07C0073I2 FR 07C0073 C FR07C0073 C FR 07C0073C FR 07C0073 C FR07C0073 C FR 07C0073C FR 07C0073 I2 FR07C0073 I2 FR 07C0073I2
Authority
FR
France
Prior art keywords
antibodies
useful
papillomavirus vaccine
mimics
diagnosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR07C0073C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georgetown University
Original Assignee
Georgetown University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25416951&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR07C0073(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Georgetown University filed Critical Georgetown University
Publication of FR07C0073I1 publication Critical patent/FR07C0073I1/fr
Application granted granted Critical
Publication of FR07C0073I2 publication Critical patent/FR07C0073I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FR07C0073C 1992-06-25 2007-12-21 Vaccin contre le papillomavirus Active FR07C0073I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90310992A 1992-06-25 1992-06-25
PCT/US1993/006109 WO1994000152A1 (fr) 1992-06-25 1993-06-24 Vaccin contre le papillomavirus

Publications (2)

Publication Number Publication Date
FR07C0073I1 FR07C0073I1 (fr) 2008-01-02
FR07C0073I2 true FR07C0073I2 (fr) 2012-08-03

Family

ID=25416951

Family Applications (1)

Application Number Title Priority Date Filing Date
FR07C0073C Active FR07C0073I2 (fr) 1992-06-25 2007-12-21 Vaccin contre le papillomavirus

Country Status (12)

Country Link
US (2) US20020068326A1 (fr)
EP (2) EP1835029A1 (fr)
AT (1) ATE380871T1 (fr)
AU (1) AU697743C (fr)
DE (9) DE122007000098I1 (fr)
DK (1) DK0647140T3 (fr)
ES (1) ES2294778T3 (fr)
FR (1) FR07C0073I2 (fr)
LU (8) LU91395I2 (fr)
NL (8) NL300318I2 (fr)
PT (1) PT647140E (fr)
WO (1) WO1994000152A1 (fr)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1471147A3 (fr) 1991-07-19 2007-03-21 The University Of Queensland Procédé de préparation d'une molécule récombinante pour l'expression du protéine L1 de l'HPV-16
US5437951A (en) * 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US6153201A (en) * 1993-03-09 2000-11-28 University Of Rochester Oral immunization with papillomavirus virus-like particles
US8062642B1 (en) 1993-03-09 2011-11-22 University Of Rochester Production of papillomavirus capsid protein and virus-like particles
DE4415743C2 (de) * 1994-05-04 1996-10-10 Deutsches Krebsforsch Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
US5888516A (en) * 1994-05-16 1999-03-30 Merck & Co. Inc. Recombinant papillomavirus vaccines
CN1152935A (zh) * 1994-05-16 1997-06-25 麦克公司 乳头状瘤病毒疫苗
AU683564B2 (en) * 1994-05-17 1997-11-13 University Of Queensland, The Recombinant papilloma virus L1
AUPM566794A0 (en) * 1994-05-17 1994-06-09 University Of Queensland, The Process and product
PL319294A1 (en) * 1994-09-22 1997-08-04 Merck & Co Inc Dna encoding the human papilloma virus of 6 a type
AU4270196A (en) 1994-10-07 1996-05-02 Lutz Gissmann Papilloma virus-like particles, fusion proteins and process for producing the same
US5820870A (en) * 1995-03-22 1998-10-13 Merck & Co., Inc. Recombinant human papillomavirus type 18 vaccine
US5840306A (en) * 1995-03-22 1998-11-24 Merck & Co., Inc. DNA encoding human papillomavirus type 18
IL117459A (en) * 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
US6908615B1 (en) 1996-03-18 2005-06-21 Merck & Co., Inc. DNA encoding human papilloma virus type 18
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
AU755679B2 (en) * 1997-07-03 2002-12-19 Medimmune, Llc Homogeneous human papilloma virus capsomere containing compositions, methods for manufacture,and the use thereof as diagnostic, prophylactic or therapy
US6228368B1 (en) 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
US7494658B2 (en) 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
CA2229955C (fr) 1998-02-20 2003-12-09 Medigene Gmbh Formulations de vaccins contenant des capsomeres de papillomavirus; methodes d'utilisation
US7182947B2 (en) 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
US6926897B1 (en) 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
CA2337101A1 (fr) 1998-07-13 2000-01-20 Loyola University Of Chicago Recepteur cellulaire du papillomavirus
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
JP2003519084A (ja) * 1998-10-16 2003-06-17 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
US7247433B2 (en) 2001-08-13 2007-07-24 University Of Rochester Transcutaneous immunization against papillomavirus with papillomavirus virus-like particles
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
DK1648931T3 (da) 2003-07-21 2011-03-07 Transgene Sa Multifunktionelle cytokiner
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
PT2484375T (pt) 2006-09-26 2018-07-09 Infectious Disease Res Inst Composição para vacina contendo adjuvante sintético
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US20100055166A1 (en) 2007-03-02 2010-03-04 Gerald Hermann Voss Novel method and compositions
CN102099053A (zh) 2008-05-26 2011-06-15 卡迪拉保健有限公司 麻疹-人乳头瘤组合疫苗
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
GB0820822D0 (en) 2008-11-13 2008-12-24 Inst Catala D Oncologia Novel product and processes
US20120115207A1 (en) * 2009-04-03 2012-05-10 Deutsches Krebsforschungszentrum Enhanced production of papillomavirus-like particles with a modified baculovirus expression system
US8722064B2 (en) 2009-06-05 2014-05-13 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
WO2011026111A1 (fr) 2009-08-31 2011-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Distribution par voie orale d'un vaccin au gros intestin pour induire une immunité mucosale
EP2556377B1 (fr) 2010-04-08 2017-07-12 University of Pittsburgh - Of the Commonwealth System of Higher Education Analyse de cellules présentatrices d'antigène des lymphocytes b
AU2012243039B2 (en) 2011-04-08 2017-07-13 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
LT2811981T (lt) 2012-02-07 2019-06-10 Infectious Disease Research Institute Pagerintos adjuvanto kompozicijos, apimančios tlr4 agonistus, ir jų panaudojimo būdai
SG11201407586WA (en) 2012-05-16 2014-12-30 Immune Design Corp Vaccines for hsv-2
EP2912069B1 (fr) 2012-10-23 2019-07-31 Emory University Conjugués de gm-csf et d'il-4, compositions et procédés associés
HK1214510A1 (zh) 2013-04-18 2016-07-29 Immune Design Corp. 用於癌症治疗的gla单一疗法
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
IL310015B1 (en) 2013-12-31 2025-10-01 Access To Advanced Health Inst Single vial formulation
CA3010905A1 (fr) 2016-02-22 2017-08-31 Boehringer Ingelheim Vetmedica Gmbh Procede d'immobilisation de biomolecules
MX2018013640A (es) 2016-05-16 2019-08-01 Infectious Disease Res Inst Liposomas pegiladas y metodos de uso.
RU2761870C2 (ru) 2016-05-16 2021-12-13 Инфекшес Дизис Рисёрч Инститьют Состав, содержащий агонист tlr, и способы применения
RU2753874C2 (ru) 2016-06-01 2021-08-24 Инфекшес Дизис Рисёрч Инститьют Наноалюмочастицы, содержащие агент, регулирующий размер
MX2019015076A (es) 2017-06-15 2020-08-03 Infectious Disease Res Inst Portadores lípidos nanoestructurados y emulsiones estables y usos de los mismos.
JP7339942B2 (ja) 2017-09-08 2023-09-06 アクセス ツー アドバンスト ヘルス インスティチュート サポニンを含むリポソーム製剤および使用方法
KR20220125149A (ko) 2019-05-25 2022-09-14 액세스 투 어드밴스드 헬스 인스티튜트 애주번트 백신 에멀션을 분무 건조시키기 위한 조성물 및 방법
AU2021337493A1 (en) 2020-09-04 2023-05-18 Access To Advanced Health Institute Co-lyophilized rna and nanostructured lipid carrier
WO2024052882A1 (fr) 2022-09-09 2024-03-14 Access To Advanced Health Institute Composition de vaccin immunogène incorporant une saponine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106626A (en) * 1980-12-22 1982-07-02 Teijin Ltd Cytotoxic protein complex and its preparation
US4455296A (en) * 1982-02-02 1984-06-19 Board Of Regents, The University Of Texas System Hybrid cell lines producing monoclonal antibodies directed against Haemophilus influenzae
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
FR2524487B1 (fr) * 1982-04-05 1985-11-22 Pasteur Institut Fragments d'adn codant pour des polypeptides contenant au moins un determinant antigenique des papillomavirus, notamment du type hpv 1a et polypeptides correspondants
US4596674A (en) * 1984-09-11 1986-06-24 Merck & Co., Inc. Immunogenic HAV peptides
DE3625257A1 (de) * 1986-07-23 1988-02-04 Behringwerke Ag Expressionsprodukte der menschlichen papillomviren typ 16 und 18, fuer diese proteine spezifische antikoerper und diese antikoerper bzw. entsprechende dna enthaltende diagnostika
NZ223009A (en) * 1986-12-31 1990-06-26 Nl Rivm Of Thoven Oligosaccharides containing d-ribose d-ribitol and phosphate units mimicing haemophilus influenzae type b antigens
EP0320942A3 (fr) * 1987-12-18 1989-10-04 American Cyanamid Company Polysaccharides et composés macromoléculaires contenant ces polysaccharides
IE910909A1 (en) * 1990-03-20 1991-09-25 Behringwerke Ag Seroreactive epitopes of human Papillomavirus (HPV) 16¹proteins
EP1471147A3 (fr) 1991-07-19 2007-03-21 The University Of Queensland Procédé de préparation d'une molécule récombinante pour l'expression du protéine L1 de l'HPV-16

Also Published As

Publication number Publication date
PT647140E (pt) 2007-12-27
DE122007000097I1 (de) 2008-03-27
LU91399I2 (fr) 2008-02-14
EP0647140B1 (fr) 2007-12-12
EP1835029A1 (fr) 2007-09-19
DE122007000095I1 (de) 2008-03-27
DE122007000094I1 (de) 2008-03-27
ES2294778T3 (es) 2008-04-01
AU1135295A (en) 1996-02-08
NL300320I1 (nl) 2008-03-03
DE122007000096I1 (de) 2008-03-27
DE122007000100I1 (de) 2008-03-27
ATE380871T1 (de) 2007-12-15
NL300319I1 (nl) 2008-03-03
NL300318I2 (nl) 2008-03-03
NL300316I1 (nl) 2008-02-01
NL300318I1 (nl) 2008-02-01
LU91393I2 (fr) 2008-02-14
DE69334192T2 (de) 2008-12-04
EP0647140A1 (fr) 1995-04-12
LU91398I2 (fr) 2008-02-14
DE122007000099I1 (de) 2008-03-27
LU91395I2 (fr) 2008-02-14
US8012679B1 (en) 2011-09-06
LU91397I2 (fr) 2008-02-14
NL300322I1 (nl) 2008-03-03
WO1994000152A1 (fr) 1994-01-06
DK0647140T3 (da) 2008-02-04
DE122007000098I1 (de) 2008-03-27
FR07C0073I1 (fr) 2008-01-02
NL300315I1 (nl) 2008-02-01
NL300321I1 (nl) 2008-03-03
AU697743C (en) 2007-06-14
DE69334192D1 (de) 2008-01-24
DE122007000101I1 (de) 2008-03-27
LU91400I2 (fr) 2008-02-14
NL300315I2 (nl) 2008-03-03
US20020068326A1 (en) 2002-06-06
LU91396I2 (fr) 2008-02-14
EP0647140A4 (fr) 1997-03-19
AU697743B2 (en) 1998-10-15
NL300317I1 (nl) 2008-02-01
LU91394I2 (fr) 2008-02-14

Similar Documents

Publication Publication Date Title
FR07C0073I2 (fr) Vaccin contre le papillomavirus
DE122008000010I1 (de) Sich selbst-zusammenbauende rekombinante hpv16 papillomavirus-hüllproteine
Schlegel et al. Protecting against canine oral papillomavirus